These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35429409)

  • 1. Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC).
    Gawdi R; Valenzuela CD; Moaven O; Stauffer JA; Del Piccolo NR; Cheung T; Corvera CU; Wisneski AD; Cha C; Russell G; Zarandi N; Dourado J; Shen P
    J Surg Oncol; 2022 Aug; 126(2):339-347. PubMed ID: 35429409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal timing of systemic therapy in resectable colorectal liver metastases.
    Ihemelandu C; Levine EA; Aklilu M; Yacoub G; Howerton R; Bolemon B; Graham M; Russell G; Shen P
    Am Surg; 2013 Apr; 79(4):414-21. PubMed ID: 23574853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer.
    Xu D; Zhu HB; Wang YY; Jin KM; Yan XL; Li J; Wang K; Xing BC
    Int J Colorectal Dis; 2022 Apr; 37(4):805-814. PubMed ID: 35188594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
    Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 9. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver.
    Baidoun F; Merjaneh Z; Nanah R; Saad AM; Abdel-Rahman O
    J Comp Eff Res; 2022 Sep; 11(13):935-951. PubMed ID: 35787069
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey.
    Bonney GK; Coldham C; Adam R; Kaiser G; Barroso E; Capussotti L; Laurent C; Verhoef C; Nuzzo G; Elias D; Lapointe R; Hubert C; Lopez-Ben S; Krawczyk M; Mirza DF;
    J Surg Oncol; 2015 May; 111(6):716-24. PubMed ID: 25864987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
    Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
    HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resectable colorectal liver metastases: optimal sequencing of chemotherapy.
    Chua TC; Morris DL
    J Gastrointest Cancer; 2012 Sep; 43(3):496-8. PubMed ID: 21365476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
    Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
    Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis.
    Reddy SK; Zorzi D; Lum YW; Barbas AS; Pawlik TM; Ribero D; Abdalla EK; Choti MA; Kemp C; Vauthey JN; Morse MA; White RR; Clary BM
    Ann Surg Oncol; 2009 Jul; 16(7):1809-19. PubMed ID: 18979139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?
    Boerner T; Zambirinis C; Gagnière J; Chou JF; Gonen M; Kemeny NE; Cercek A; Connell LC; Kingham TP; Allen PJ; Balachandran VP; Drebin J; Jarnagin WR; D'Angelica MI
    HPB (Oxford); 2021 Apr; 23(4):601-608. PubMed ID: 32943326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
    Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
    Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
    Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies.
    Nigri G; Petrucciani N; Ferla F; La Torre M; Aurello P; Ramacciato G
    Surgeon; 2015 Apr; 13(2):83-90. PubMed ID: 25257725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.